Why the study?
Natriuretic peptides have recognized limitations for HF diagnostics, risk stratification, and prognosis, prompting evaluation of new candidate biomarkers such as soluble ST2.
Does soluble ST2 measurement improve diagnostics, risk stratification, and prognosis evaluation in patients with chronic heart failure?
Does soluble ST2 measurement improve diagnostics, risk stratification, and prognosis evaluation in patients with chronic heart failure?
Soluble ST2 is a promising biomarker of mechanical myocardial stress for diagnostics and risk stratification in chronic heart failure.
Answers are grounded in this paper and cite their sources.
Supports expanded sST2 research for CHF risk stratification; leaves open whether measurement improves outcomes or practice.
This review focuses on possibilities of using soluble ST2 as a HF marker for diagnostics, stratification of risk of adverse events, and for evaluation of prognosis and treatment effectiveness in patients with CHF. Circulating biomarkers are an essential element of algorithms for diagnostics, stratification of risk, and evaluation of prognosis in patients with HF. The recognized "gold standard", natriuretic peptides, has several well-known limitations, and multiple new candidate biomarkers have appeared in recent years. Soluble ST2, a marker of "mechanical myocardial stress", is considered as one of the most promising new biomarkers. This review discusses possibilities of using it in clinical practice in CHF patients.
No takes yet. Share an insight, caveat, or question.
Камардинов et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: